阿德福韦酯治疗乙肝的研究进展

Research Progress of the Treatment of Adeforvit Dipivoxil for Hepatites B

乙肝是我国乃至世界突出的公共卫生健康问题。抗病毒治疗是乙肝治疗的主要手段,既往主要是干扰素(inteferon,IFN)和拉米夫定(lamivudine,3TC),但由于其副作用较多、耐受性差、耐药变异性差而使使用受到限制。阿德福韦酯(ADV)是近年来研发应用于治疗乙肝的新药,它通过与dATP竞争逆转录酶结合位点,结合并阻断DNA链的延伸而抑制病毒的复制。临床观察提示它对慢性乙肝代偿期和失代偿期及3TC耐药均有效。本文就ADV抗乙肝病毒治疗,从药理学、耐药变异、临床疗效等进行综述。

Hepatitis B is a prominent public health problem in China and all of the world. Antiviral therapy is the primary mean of treatment of hepatitis B,mainly methods in the past were interferon（intefreron,IFN）and lamivudine（lamivudine,3TC）. Due to more side effects,poor tolerability and poor resistance variation their using are limited. Adefovir dipivoxil（ADV）,which is a new drug research and development,is used to treat hepatitis B in recent years,h competes with dATP for reverse transcriptase binding sites,bind to and block the DNA chain extension and inhibit virus replication. Clinical obserations suggest it for compensatory and decompensated cirrhosis of chronic hepatitis B and 3TC resistance are valid. This article reviewes on ADV anti-HBV therapy,from pharmacology,drug resistance mutation, clinical efficacy, etc.